Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2025 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

Arcutis today announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting (AAD).
July 23, 2024 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis today announced the submission of an sNDA in scalp and body psoriasis.
November 03, 2023 07:30 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update

Arcutis today reported financial results for the quarter ended September 30, 2023, and provided a business update.
October 13, 2023 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress

Arcutis announced new data from its pivotal ARRECTOR Phase 3 trial of roflumilast foam 0.3% for treatment of adults/adolescents with scalp/body psoriasis.
August 10, 2023 08:16 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia

Arcutis to receive $30 million upfront payment and is eligible to receive potential development and commercial milestone payments, as well as double digit tiered royalties WESTLAKE VILLAGE,...
August 08, 2023 16:02 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update

Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $4.8 million, a 72% increase compared to the first quarter of...
April 18, 2023 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

FDA has set a target action date of December 16, 2023NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foamIf approved, roflumilast foam...
March 09, 2023 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitisNew national survey insights depicting disease burden, path to diagnosis...
February 28, 2023 16:02 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Achieved net revenues of $3.0 million for ZORYVE® (roflumilast) cream 0.3% in the first full quarter since the August 2022 launch, driven by continued unit demand growthSecured expanded commercial...
February 21, 2023 08:00 ET | Source: Arcutis Biotherapeutics, Inc.

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

Seborrheic dermatitis is an inflammatory skin disease affecting more than 10 million individuals in the United StatesIf approved, roflumilast foam would be the first topical drug for seborrheic...

Next Page keyboard_arrow_right